Zevra Therapeutics (ZVRA) Accumulated Expenses (2014 - 2024)

Zevra Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $6.1 million for Q4 2024.

• Quarterly Accumulated Expenses fell 42.59% year-over-year to $6.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6.1 million (down 42.59% YoY) and the FY2024 annual result came in at $6.1 million, down 42.59% from the prior year.
• Accumulated Expenses was $6.1 million for Q4 2024 at Zevra Therapeutics, down from $10.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.7 million in Q4 2023 and bottomed at $1.1 million in Q4 2021.
• A 5-year average of $4.1 million and a median of $1.7 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 537.84% — and 2024, when it tumbled 42.59%.
• Zevra Therapeutics' Accumulated Expenses stood at $1.2 million in 2020, then fell by 8.98% to $1.1 million in 2021, then soared by 58.73% to $1.7 million in 2022, then jumped by 537.84% to $10.7 million in 2023, then tumbled by 42.59% to $6.1 million in 2024.
• Business Quant data shows ZVRA's Accumulated Expenses at $6.1 million in Q4 2024, $10.7 million in Q4 2023, and $1.7 million in Q4 2022.